Skip to main content

FDA Approvals

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

Trodelvy Receives New Indication for Advanced Urothelial Cancer

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma

Page 12 of 53
Results 111 - 120 of 524